Sarepta Therapeutics halted shipments of its DMD gene therapy Elevidys to non-ambulatory patients following a second fatal case of acute liver failure. Both deaths occurred in adolescent boys with advanced disease stages and raise serious safety concerns that have shaken the Duchenne muscular dystrophy community. Sarepta is proposing immunosuppressive regimens to mitigate liver injury risks. Wall Street responded sharply with significant stock declines, reflecting uncertainty over future FDA regulatory actions and the therapy's path forward.